Key result
QardioArm mobile device meets ESH validation requirements for blood pressure monitoring in T2D.
Why the study?
Home blood pressure monitoring provides benefits in populations prone to hypertension, motivating validation of the QardioArm mobile device in individuals with noninsulin-dependent type 2 diabetes under European Society of Hypertension guidelines.
Does the QardioArm mobile device accurately measure blood pressure and heart rate compared to a standard digital sphygmomanometer in patients with noninsulin-dependent type 2 diabetes?
Observational (n=33)
Does the QardioArm mobile device accurately measure blood pressure and heart rate compared to a standard digital sphygmomanometer in patients with noninsulin-dependent type 2 diabetes?
The QardioArm mobile device is a valid tool for home blood pressure and heart rate monitoring in patients with noninsulin-dependent type 2 diabetes.
Answers are grounded in this paper and cite their sources.
Supports QardioArm for home BP monitoring in T2DM; leaves open broader validation in larger prospective studies.
BACKGROUND Home blood pressure monitoring has many benefits, even more so, in populations prone to high blood pressure, such as persons with diabetes. OBJECTIVE The purpose of this research was to validate the QardioArm mobile device in a sample of individuals with noninsulin-dependent type 2 diabetes in accordance with the guidelines of the second International Protocol of the European Society of Hypertension. METHODS The sample consisted of 33 patients with type 2 diabetes. To evaluate the validity of QardioArm by comparing its data with that obtained with a digital sphygmomanometer (Omron M3 Intellisense), two nurses collected diastolic blood pressure, systolic blood pressure, and heart rate with both devices. RESULTS The analysis indicated that the test device QardioArm met all the validation requirements using a sample population with type 2 diabetes. CONCLUSIONS This paper reports the first validation of QardioArm in a population of individuals with noninsulin-dependent type 2 diabetes. QardioArm for home monitoring of blood pressure and heart rate met the requirements of the second International Protocol of the European Society of Hypertension.
No takes yet. Share an insight, caveat, or question.
Mazoteras‐Pardo et al. (2020) conducted an observational in Noninsulin-dependent type 2 diabetes (n=33). QardioArm mobile device vs. Omron M3 Intellisense digital sphygmomanometer was evaluated on Validation according to the second International Protocol of the European Society of Hypertension. The QardioArm mobile device met all validation requirements of the second International Protocol of the European Society of Hypertension for blood pressure monitoring in 33 patients with type 2 diabetes.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: